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INTRODUCTION
Plasmodium vivax is a significant cause of morbidity 
due to malaria in northern Thailand which has a 
population of 4.74 million with mixed ethnic Thai 
and hill-tribe minority groups. Early in the new 
millennium, the relative prevalence of P. falciparum 
and P. vivax came close to equilibrium, and recently, 
P.vivax became the leading species. In 2005, 2,699 
microscopically-confirmed cases were reported, of 
which 46% were due to P. falciparum, and 54% were 
due to P. vivax (1). Malaria due to P. vivax has placed 
the huge burden on health in northern Thailand. 
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ABSTRACT
Vivax malaria is a significant cause of morbidity due to malaria in northern Thailand, accounting for ap-
proximately 50% of all malaria cases. The objective of this study was to determine the behavioural factors 
associated with adherence to the standard 14-day course of chloroquine and primaquine, prescribed from 
malaria clinics, among patients with vivax malaria. A retrospective study was conducted among 206 pa-
tients living in Muang and Mae Sa Riang districts of Mae Hon Son province in northern Thailand. Data on 
adherence and potential behavioural factors relating to adherence were collected using a structured inter-
viewer-administered questionnaire and supplemented with qualitative data from focus-group interviews. 
The results indicated that 76.21% of the 206 patients with vivax malaria did not complete the medication 
course. The adherence of the patients was associated with knowledge scores of malaria (adjusted odds ratio 
[AOR]=2.2, 95% confidence interval [CI] 1.1-4.5) and accessing drug prescription scores (AOR=5.6, 95% CI 
2.13-15.3). Therefore, further effort is needed to educate patients with vivax malaria on knowledge of ma-
laria and its treatment with simple health messages and encourage them to adhere to their treatment.
Key words: Antimalarials; Chloroquine; Drug adherence; Drug Therapy; Primaquine; Malaria; Retrospec-
tive studies; Vivax malaria; Thailand
In provinces on the Thai-Myanmar border where 
the transmission of malaria is high, the proportion 
of P. vivax-associated cases has increased slightly 
over time. Transmission is closely associated with 
forest locations where there are abundant breeding 
sites of the vectors of malarial parasites (2), various 
occupational factors that encourage movement of 
population or influx of refugees, socioeconomic 
factors affecting malaria (3,4), and high degree of 
drug resistance (5).
The Mae Hong Son province is located on the 
Thai-Myanmar border in northern Thailand. Sur-
veillance reports indicate that malaria has become 
endemic throughout the Mae Hong Son province. 
The incidence rates of malaria in the province were 
24.4, 14.2, 10.04, 8.52, and 8.32 per 1,000 people 
during 2001-2005 respectively (1). These incidence 
rates are significantly higher than that in the na-
tional malaria-control programme goal of lower 
than 1 per 1,000 people (6). 
Prompt and effective treatment of malaria remains a 
challenge for  the malaria-control programmes (7). Khantikul N et al. Adherence to antimalarial drug therapy in Thailand
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Case management is one of the cornerstones of 
malaria control in this part of the world, with the 
goal to reduce morbidity and mortality through 
prompt diagnosis and effective management of 
acute clinical episodes with antimalarial drugs (8). 
Chloroquine and primaquine are still effective for 
treating patients with vivax malaria in Thailand 
(9,10). Although drug resistance in P. vivax has not 
yet been reported in Thailand (11), accurate assess-
ment of adherence behaviour is necessary for effec- 
tive and efficient treatment (12). However, there   
are a few systematic studies on adherence of pa-
tients to antivivax malaria medications. Therefore, 
we conducted a retrospective study to define the 
factors influencing the adherence and non-adher-
ence to drug treatment in patients with vivax ma-
laria. The results from this research will be used for 
implementing a health-promotion programme to 
enhance adherence to antivivax malaria drugs.
MATERIALS AND METHODS
Study site 
This retrospective study was conducted during 
May-September 2006 in Muang and Mae Sa Riang 
districts, Mae Hong Son province of north Thai-
land. The Mae Sa Riang district is located 190 km 
south of Muang district. These areas are of mixed 
ethnic groups that include Thai, Karen, and Shan 
(Thai Yai) and are similar in culture, demograph-
ics, and natural environment. The settings were 
selected because of high transmission of vivax 
malaria. 
Selection of sample
The initial sample comprised all records of 379 
vivax malaria patients who received treatment from 
three malaria clinics in Muang district and two in 
Mae Sa Riang district during 1 January 2005–31 
July 2006; cases were diagnosed by thick blood 
smear examinations and had single infection with 
P. vivax. Of the 379 patients with vivax malaria, 206 
were eligible for inclusion in the study. The remain-
ing 173 cases were excluded because 135 were not 
residents, 12 had mixed vivax and falciparum infec-
tions, 16 were treated at hospitals, and 10 refused 
to participate in the study. Focus-group discussions 
(FGDs) were conducted in September 2006 to col-
lect more information and triangulate with quan-
titative data. We conducted FGDs four times with 
the participants who were randomly selected from 
those of 206 interviewed patients after the collec-
tion of quantitative data. We sampled them from 
the list of our patients and then made an appoint-
ment. Village health volunteers assisted us to call 
them to a meeting place. The Mae Sa Riang district 
had two FGDs: the first one had seven adherent pa-
tients, and the second one had eight non-adherent 
patients. The Muang district conducted two groups: 
the first one was conducted with eight adherent pa-
tients, and the other one with seven non-adherent 
patients. 
Training of interviewers
Four skilled intervierwers were trained to admin-
ister the structured questionnaire, the use of in-
formed consent forms, procedures of questioning 
the participants, and interacting with four inter-
preters. All the four interpreters received train-
ing at the same time with the interviewers while 
the trainer had taught them some simple scientific 
terms and cross-checked the meaning between the 
both, such as symptoms of malaria, primaquine, 
chloroquine, etc. One interpreter accompanied an 
interviewer to visit homes of patients throughout 
the study. All the interviewers were able to listen 
terms/dialects of native languages; however, they 
might not speak the native language as well as did 
the interpreters.
Instruments
We used an interviewer-administered structured 
questionnaire for data collection and developed 
focus-group guidelines (13) to collect qualitative 
data. The questionnaire was designed to elicit in-
formation from participants on behaviours relating 
to adherence to antimalarial medicines prescribed 
by the malaria clinic. The structured questionnaire 
was pretested in a distant similar geographical dis-
trict in Chiang Dao, Chiang Mai province. The 
questionnaire consisted of questions relating to 
general knowledge of malaria, perception towards 
susceptibility and severity of malaria, benefit from 
and barrier to treatment, and an access to informa-
tion on antimalarial medications and adherence 
to drug. Scores on knowledge about malaria (14) 
were assessed using 15 questions (alpha reliabili-
ty=0.82) that asked the participants about aetio-
logy of malaria, breeding places of malaria vectors, 
and prevention and control of malaria. The access 
to information on malaria-medication scores (8) 
was calculated using eight questions (alpha reli-
ability=0.61). Each question was scored with 1 for a 
correct answer or 0 for an incorrect one. Therefore, 
the knowledge score ranged from 0 to 15, and the 
access to information on antimalarial medication 
scores ranged from 0 to 8. The knowledge of ma-
laria and the access to information on antimalarial Khantikul N et al. Adherence to antimalarial drug therapy in Thailand
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medication scores were categorized into two levels 
using cut-off points at mean scores. Perception on 
malaria treatment referred to 15 questions (alpha 
reliability=0.64), including perceived susceptibility 
which refers to an individual perceiving her/him-
self vulnerable to contract the disease, perceived 
seriousness which means an individual’s belief that 
malaria is serious, perceived benefit from treatment 
which refers to the degree to which an individual 
believes the effectiveness of medications, and per-
ceived barriers associated with adherence, such as 
forgetting to take the medicine, getting side-ef-
fects, and lack of access to antimalarial treatment. 
The malaria-perception scale-related questions 
use a Likert-type scale (15). The possible range of 
scores for the perception scale was 15 to 45, and 
this scale was also dichotomized at the mean scores 
as mentioned above. We also collected qualitative 
data through FGDs with adherent and non-ad-
herent participants from the two districts. We de-
fined adherence as a completion of the prescribed 
medication regimen without deviation. The drug 
regimen consisted of chloroquine 25 mg base/kg 
body-weight per day taken for three days and pri-
maquine 0.25 mg/kg for 14 days.
Data collection
An interviewer administered the structured ques-
tionnaire at the patient’s house. We collected name, 
address, and history of malaria of each eligible pa-
tient from the patient-records that would bring us 
to the patient’s home. When visiting for interview, 
206 patients participated after 10 patients refused 
the consent. A supervisory team monitored the 
interviewers and checked the questionnaire for 
consistency. In the FGDs, the principal investigator 
who acted as the moderator worked with two as-
sistants sitting in circle with the participants. Dur-
ing about one hour of discussion, information was 
taped and noted.
Statistical analyses
The Stata software (version 8.0) (Stata Corporation, 
College Station, TX, USA) was used for all statistical 
analyses. Chi-square tests were used for identifying 
variables associated with adherence to drug, includ-
ing knowledge of malaria, perception of malaria, 
drug-taking behaviour, healthcare service, and so-
cial support. The variables that were significantly 
associated with adherence to drug in bivariate anal-
yses (p<0.05) were selected for further multivariate 
analyses using unconditional logistic regression to 
assess confounding and interactions between the 
determinants. Odds ratios and 95% confidence in-
tervals were used for quantifying associations. All 
statistics were two-sided tests with a significance 
level of alpha=0.05. Data from the FGDs were ana-
lyzed using a deduction method.
Ethical considerations
The Ethical Committee of the Mahidol Univer-
sity reviewed and approved the procedures of this 
study. Patients were informed about the purpose of 
the study, and participants provided written con-
sent before participating in the interview process.
RESULTS
Demographics
Of the 206 patients with vivax malaria, 133 (64.5%) 
were males and 155 (75.2%) were non-Thai com-
prising Karen (34.0%), Thai Yai (27.7%), and others 
(3.4%); 76.2% of the patients with vivax malaria 
did not complete the medication course whereas 
23.8% adhered to it (Table 1). Languages used in-
cluded Thai, Karen, and Thai Yai. Over 40% had 
never attended any school. The median age of the 
study participants was 36 (range 11-88) years, and 
the median family-size was 4 (range 1-7). There was 
some variability across the study sites in the medi-
an monthly income. The lowest monthly income 
was zero, the median was 1,350 Baht (US$ 39), and 
the highest was 24,000 Baht (US$ 705). The mean 
number of years of residency at the respondent’s 
current location was 40 years. About 64.0% were 
farmers who worked with forestry-related jobs. 
Knowledge
There was a significant difference in knowledge on 
malaria between the adherent and the non-adher-
ent group (Table 2). Participants who adhered to 
their malaria medication were more likely than non-
adherent participants to correctly answer that mos-
quito bites are a cause leading to malaria (p=0.015), 
that one cannot contract malaria by drinking water 
from a stream in the forest (p=0.001), that malaria 
vectors breed in a slow-running stream (p=0.001) 
and in animal footprints in the forest (p=0.008), 
and that sleeping under a mosquito net (p=0.011) 
and using mosquito-repellent (p=0.040) can pre-
vent malaria. Both adherent and non-adherent 
groups recognized that headaches, fever, and 
shivering were common signs and symptoms of 
malaria.
Perceptions
The figure illustrates that the overall mean percep-
tion score differed significantly between the ad-Khantikul N et al. Adherence to antimalarial drug therapy in Thailand
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Table 1. Associations between demographic characteristics of patients with vivax malaria and adher-
ence to drug, Mae Hong Son province, northern Thailand, 2006
Demographic characteristics
Non-adherent (76.2%) Adherent (23.8%) Chi-square
 (p value)   No. %   No. %
Gender
   Male 98 62.4 35 71.4 0.249
   Female 59 37.6 14 28.6
Age-group (years)
   11-35 79 50.3 20 40.8 0.245
   36-88 78 49.7 29 59.2
Ethnicity
   Thai 39 24.8 12 24.5 0.960
   Non-Thai 118 75.2 37 75.5
Occupation
   Not forestry-related* 62 39.5 12 24.5 0.056
   Forestry-related 95 60.5 37 75.5
Educational level
   No schooling 71 45.2 17 34.7 0.193
   Primary schooling and above    86 54.8 32 65.3
Income per month (Baht)
   <1,000  74 47.1 24 49.0 0.821
   >1,000  83 52.9 25 51.0
Number of family members
   <5  103 65.6 29 59.2 0.413
   >5  54 34.4 20 40.8
*Includes students, housewives, government officials, employees, and unemployed
Table 2. Comparison of general knowledge of malaria and adherence to drug among patients with vivax 
malaria, Mae Hong Son province, 2006
Knowledge of malaria
Number that answered correctly
Chi-square
(p value)
Non-adherent Adherent
 No. %  No. %
Malaria transmission
   Mosquito bites cause malaria 110 70.1 43 87.8 0.015
   Drinking raw water from a stream in  the forest   
      is not a risk
35 22.3 25 51.0 0.001
Breeding place for malaria vectors
   Vectors breed in slow-running streams 45 28.7 27 55.1 0.001
   Vectors breed in animal footprints  81 51.6 36 73.5 0.008
Protective methods against malaria
   Sleeping under mosquito net  104 66.2 42 85.7 0.011
   Using mosquito-repellent 96 61.1 38 77.6 0.040
Signs and symptoms of malaria
   Headache 133 84.7 45 91.8 0.241
   Fever 138 87.9 47 95.5 0.173
   Shivering 130 82.8 43 87.8 0.507Khantikul N et al. Adherence to antimalarial drug therapy in Thailand
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herent and the non-adherent patients (p=0.011). 
Those with good perception were 2.2 times (95% 
CI 1.1-4.9) more likely to adhere to antimalarial 
medications than those with poor perception. Af-
ter stratifying the results into perception subcate-
gories, perceived susceptibility and perceived sever-
ity of malaria were not associated with adherence. 
However, those with good perceived benefit from 
antimalarial medications were 3.3 times (95% CI 
1.6-6.7) more likely to adhere to the medications 
than those with poor perceived benefits. Similarly, 
those with good perceived barriers to antimalarial 
medications were 1.91 times (95% CI 1.0-3.9) more 
likely to adhere to the medications than those with 
poor-perceived barriers.
Access
Table 3 describes access to information received 
on antimalarial medications by patients with vivax 
malaria after visiting malaria clinics, stratified by 
type of adherence. We asked whether the patients 
could recall and explain the drugs received from the 
malaria officers. The proportions of 75.5% of the 
adherent patients (n=37) higher than 55.4% of the 
non-adherent patients (n=87) stated taking chloro-
quine and primaquine for full 14 days (p=0.013), 
could recall the colour of the pills (83.7% vs 52.2%, 
p=0.000), and could clearly understand and re-
call the labels and instructions (81.6% vs 57.3%, 
p=0.002). For other questions on access to infor-
mation, the proportions were statistically similar. 
Further analysis of the summary data (Table 4) re-
vealed that those with high access to information 
on antimalarial medication scores were 5.6 times 
(95% CI 2.0-18.9) more likely to adhere to treat-
ment than those with low access scores. 
Adherence
After adjusting for demographic factors, knowledge 
scores, perception scores, and access to information 
on antimalarial medication scores, adherence of pa-
tients was significantly associated with knowledge 
of malaria scores (adjusted OR=2.2, 95% CI 1.1-4.5), 
and access to information on antimalarial medica-
tion scores (AOR=5.6, 95% CI 2.1-15.3). Patients 
having higher or equal to 38 perception scores were 
1.91 times (AOR=1.9, 95% CI 0.9-3.8) more likely 
to be adherent than those with lower than 38 per-
ception scores; these results were not statistically 
significant (Table 4).
Focus-group discussions
The qualitative data from FGDs in two districts of 
A. Comparison of perceived susceptibility of malaria
Poor perception Good perception Poor perception Good perception
Poor perception Good perception Poor perception Good perception
Non-adherence group
B. Comparison of perceived severity of malaria
C. Comparison of perceived beneﬁt of malaria
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D. Comparison of perceived barriers of malaria
     treatment*
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Fig. Comparisons between poor and good perceptions in term of: (A) Perceived susceptibility of malaria,
        (B) Perceived severity of malaria, (C) Perceived beneﬁt of malaria treatment, and (D) Perceived
        barriers to malaria treatment among patients with vivax malaria in Mae Hong Son province, 2006
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the province fostered the findings from question-
naire interviews for perceptions of benefits and 
barriers to the medications. The perceived benefits 
appeared to be related to confidence in drug-effec-
tiveness among the adherent patients. These cases 
perceived barriers to treatment when they got sick 
from side-effect of chloroquine; however, they were 
not feared to fight against it, for example, trying to 
take drugs before bed or taking drugs immediately 
after a meal. A female respondent stated, “Medica-
tion course takes so long to finish, I got vomiting 
only in the first three days but I tried to finish all 
the drugs.” A man who perceived that going to 
treatment at the clinic was time-consuming, stated, 
“I have to go for treatment anyway, even I miss my 
job for one day.”
DISCUSSION
P. vivax-associated infection has placed huge bur-
dens on the health, longevity, and general prosperi-
ty in large segments of the human population (16). 
Adherence to antimalarial medications remains 
an important component of malaria control. Ac-
cording to the policy of the Thai National Malaria 
Control Programme, all microscopically-confirmed 
cases of vivax malaria receive prompt treatment 
following the National Drug Guidelines of the 
Ministry of Public Health (6). The ability of people 
to follow a given treatment regimen has been stud-
ied for some time. ‘Compliance’, ‘concordance’, 
and ‘adherence’ have all been used for describing 
their concepts (17). Adherence is difficult to mea-
Table 3.  Comparisons of access to information on antimalarial medications and adherence to drug 
among patients with vivax malaria, Mae Hong Son province, 2006
Determinant
Non-adherent Adherent
p value
 No. %  No. %
Stated taking chloroquine and primaquine for full 14 days 87 55.4 37 75.5 0.013
Could recall colour of antimalarial pills correctly 82 52.2 41 83.7 0.000
Received drug package from malaria clinics correctly 124 79.0 42 85.7 0.408
Took the first dose of antimalarial drug immediately after  
   diagnosis 122 77.7 38 77.6 1.000
Clearly understood drug label and instructions 90 57.3 40 81.6 0.002
Malaria officer clearly explained how to complete 
treatment for malaria 130 82.8 45 91.8 0.169
Understood all details 121 77.1 43 87.8 0.154
Took drug after meal to decrease side-effects of treatment  
   for malaria 98 62.4 35 71.4 0.306
Table 4. Logistic regression analysis to identify determinants for knowledge of malaria, perception of 
malaria, access to information on prescription, and adherence to drug among patients with 
vivax malaria
Variable
Unadjusted Adjusted
OR 95% CI OR     95% CI
Knowledge scores
   Poor (<10) 1.0 1.0
   Good (10-15) 2.1 1.0-4.3 2.2 1.1-4.5
Perception scores 
   Low (<38) 1.0 1.0
   High (38-45) 2.3 1.1-4.9 1.9 0.9-3.8
Access to drug prescription scores
   Poor (<6) 1.0 1.0
   Good (6-8) 5.6 2.0-18.9 5.6 2.1-15.3
CI=Confidence interval; OR=Odds ratioKhantikul N et al. Adherence to antimalarial drug therapy in Thailand
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sure as the techniques to measure adherence have 
drawbacks (18). In this study, adherence behaviour 
was assessed using self-report measures that have 
been standardized, validated, and well-accepted in 
the adherence literature (19). Patients were classi-
fied as ‘adhering’ if they followed the medication 
instructions exactly by taking the standard 14-day 
course of chloroquine (25 mg base/kg for 3 days) 
and primaquine (0.25 mg/kg daily for 14 days) (20). 
However, the large majority (76.2%) of patients 
with vivax malaria in this study were classified as 
‘non-adhering’. The consequences of non-adher-
ence to antimalarial medication may not only be 
dangerous for the health of the patient, but may 
also dramatically increase the financial cost for 
public-health services (11). 
The demographic factors have not been shown as 
predictors of adherence. This finding was similar to 
the study of Haynes (21) that found no relation-
ship between adherence and race, sex, educational 
experience, intelligence, marital status, occupa-
tional status, income, and ethnic or cultural back-
ground and was also similar to results reported by 
Simsek (22). However, in bivariate analyses, only 
those who had forestry-related occupations were 
more likely to adhere to treatment than those not 
involved in forestry-related occupations, with a 
p value that closely approaches statistical signifi-
cance (p=0.056). In contrast, the participants not 
involved in forestry-related occupations from FGDs 
indicated that, since they worked in or near areas 
with high transmission of malaria, they wanted to 
avoid having chronic malaria which may prevent 
them from working; so, they had a greater incen-
tive to complete the medications for malaria to 
avoid missed work days. 
Results of this study also suggest that general knowl-
edge of malaria may be associated with adherence 
to drug. Symptoms commonly relating to malaria 
were fever, headache, and shivering, specifically fe-
ver that re-appears with certain regularity. Both ad-
herent and non-adherent participants were equally 
knowledgeable about the signs and symptoms of 
malaria. Prior studies have shown that popula-
tions living in malarial-prone areas are generally 
knowledgeable about the signs and symptoms of 
malaria. Guatemala and Turkey reported recogni-
tion of symptoms of malaria in more than 80% 
of the study population (22,23). Outside of signs 
and symptoms of malaria, there is, however, a fair 
amount of misinformation on aetiology of malaria. 
For example, a significant number of respondents 
(p<0.05) reported that malaria can be contracted by 
drinking untreated water from streams, ponds, or 
groundwater in the forest. Only 50% of the adher-
ent group knew breeding places of malaria vectors 
and protective measures against malaria (24). Nev-
ertheless, those who were adherent to medication 
for vivax malaria were significantly more knowl-
edgeable in aetiology of malaria than those who 
were non-adherent, indicating that better educa-
tion in aetiology of malaria may increase adher-
ence to treatment (AOR=2.24, 95% CI 1.11-4.50). 
The information from FGDs supported that the 
participants did not know about drug of treatment, 
action of drug, the way how to take it correctly, re-
lapsing fever, and what are chloroquine and prima-
quine for. They might not be aware of the hazards 
of not adhering to the treatment of malaria.
Perceived benefits from effectiveness of medication 
and barriers of forgetting to take medications were 
related to beliefs about receiving treatment at the 
malaria clinic and how treatment would affect the 
well-being of an individual. Adherent and non-ad-
herent patients answered that they went to malaria 
clinics for medical attention when ill. The malar-
ia clinics in this study are located closely to their 
houses and accessible on the well-paved roads. In 
terms of the Health Belief Model (25), cues to ac-
tion from sickness of their relatives are the factors 
that might encourage an individual to act in the 
face of their perception of the severity of vivax ma-
laria. In our study, adherence was significantly as-
sociated with perceived benefit from and perceived 
barrier to malaria-treatment scores (p<0.05). The 
participants had confidence with treatment of ma-
laria from the malaria clinic. This may provide a 
further path of action to increase drug-adherence 
behaviour among patients with vivax malaria. 
Further, more information on access to antima-
larial medications among patients with vivax ma-
laria, after visiting malaria clinics, was gathered in 
focus groups. We asked whether the patients could 
describe the treatment for malaria and what infor-
mation they received from malaria officers. The 
adherent group could recall the number of days to 
complete taking chloroquine and primaquine bet-
ter than those in the non-adherent group. Atreja et 
al. noted using a multidisciplinary approach with 
the ‘SIMPLE strategy’ (S=Simplifying regimen char-
acteristics, I=Imparting knowledge, M=Modifying 
patients’ beliefs, P=Patients’ communication, 
L=Leaving the bias, and E=Evaluating adherence 
in the context of a healthcare team and system-re-
lated factors) to enhance drug adherence (26). The 
problem of poor adherence may be overcome with Khantikul N et al. Adherence to antimalarial drug therapy in Thailand
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simple health messages even when the majority of 
individuals are illiterate and lack formal education 
(27). 
In northern Thailand, when medication is admin-
istered to patients at malaria clinics, verbal instruc-
tions are given, and little written instructions 
are printed on the 4-5 plastic bags that contain 
the actual drugs. These bags containing drugs are 
sometimes divided according to meals. However, 
our study indicates that information, education, 
and communication (IEC) materials available 
to patients are not used at malaria clinics. One 
patient in the non-adherent group stated, “I con-
fused with several bags given from malaria clinic. 
I could not understand how to take antimalarial 
prescriptions after I went home. I could not re-
member which medicines should be taken and 
when.” Another one said, “When I feel better, I 
always forget to take antimalarial drugs on time. I 
remembered that I did not finish antimalarial 
drugs. I did not know what happened to me when 
I did not finish all medicines.” Rates of low ad-
herence may indicate that instructions provided 
to patients are too complicated for them to un-
derstand, and the language used was a barrier for 
some patients, particularly among ethnic minority 
groups. Even among patients who speak Thai, lit-
eracy may be an issue, similar to other studies that 
have reported difficulties due to limited literacy 
among patients and their inability to read written 
instructions (28,29). Furthermore, qualitative data 
from focus-group interviews suggest that patients 
were not able to understand or remember the in-
structions and suggestions from malaria officers 
because patients were so ill when they were receiv-
ing medications, regardless of literacy or language 
used. Moreover, these may be overcome by tailor-
ing education to the patient’s level of understand-
ing for instructions about medicine-use. The next 
step is, therefore, to look for different models of 
IEC programmes for these target groups.
In interviews with subjects, we found that 55.8% 
of the patients with vivax malaria were satisfied 
with the healthcare services from the malaria 
clinics. Critical to patients’ adherence is good 
communication between malaria officers and pa-
tients. Healthcare providers play a unique and im-
portant role in assisting healthy behaviour chang-
es among patients (30-32). The role of healthcare 
providers should go beyond case-investigations 
and prompt treatment to ensure that people are 
receiving the effective drug regimen to treat ma-
laria, and interventions that aid people in taking 
the correct treatment will help maximize their ef-
fectiveness. 
This study had both limitations and strengths. 
The strength of this study is that, to date, this is 
the only study in Thailand that looks at social fac-
tors for adherence to treatment for vivax malaria. 
This study also includes a sufficiently large num-
ber of minority subjects with an adequate number 
of participants. Furthermore, both qualitative and 
quantitative data were collected. Since this study 
is retrospective and the participants were asked to 
recall actions that occurred up to a year in the past, 
recall bias is a potential issue. Those who did not 
adhere to the treatments were more likely to incor-
rectly recall their treatments. Also, those who did 
not adhere to the treatments may be less likely to 
participate; so, there is potential for some partici-
pation bias. Finally, because of various languages 
spoken by the study participants, there may be 
information biases due to interpretation issues, al-
though any bias due to interpretation is most likely 
non-differential. 
The success or failure of any public-health pro-
gramme is largely determined by effective use of 
services offered to the public. This principle is es-
pecially relevant in treating malaria because the 
prompt use of effective drugs greatly reduces the 
incidence of severe and complicated disease (12). 
Adherence to antimalarial medication has been 
correlated to knowledge of malaria, access to infor-
mation on medication for malaria, perceived bene-
fit from medication, and perceived barriers to treat-
ment. Non-adherent patients with vivax malaria 
are at an increasing risk of consequent relapses, in-
creasing morbidity due to malaria, and rising over-
all cost of treatment. However, changing human 
behaviours  to increase adherence can be difficult, 
and to maintain these behavioural changes is even 
more challenging. A sustainable tool to overcome 
these challenges is the use of IEC strategies. The re-
sults of this study have given us insights into the 
social factors associated with adherence to antima-
larial medications and can, therefore, provide base-
line data for planning new strategies to improving 
adherence to antimalarial medications. Specifically, 
we can use these data to develop tailored educa-
tional materials oriented towards strengthening 
knowledge of malaria among at-risk populations. 
Finally, to overcome behavioural barriers to adher-
ence to antimalarial medications, improved IEC 
between healthcare providers and patients are criti-
cal to enhance the ability of patients to follow the 
medication regimen.Khantikul N et al. Adherence to antimalarial drug therapy in Thailand
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